ロード中...
Treatment of walking impairment in multiple sclerosis with dalfampridine
Potassium channel blockade has long been considered a potential therapeutic strategy for treatment of multiple sclerosis (MS) based on the pathophysiology of demyelinated axons. Dalfampridine, which is also known as fampridine or 4-aminopyridine (4-AP), is the potassium channel blocker that has been...
保存先:
| 第一著者: | |
|---|---|
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
SAGE Publishing
2011-03-01
|
| シリーズ: | Therapeutic Advances in Neurological Disorders |
| オンライン･アクセス: | https://doi.org/10.1177/1756285611403960 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|